Skip to content

Understanding Sarcopenic Obesity in PCOS and the Benefits of Personalized Lifestyle Changes for Treatment

Prevalence of Sarcopenic obesity in patients with Polycystic ovary syndrome and efficacy of individualised lifestyle modifications for treatment of Sarcopenic obesity: A Matched Case Control and pre-post intervention study. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079478
Enrollment
140
Registered
2025-01-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: Diet and Exercise : Duration/Frequency of the proposed intervention: From baseline to 12 weeks A. Dietary Intervention: A.1 Diet Type: Low Glycemic Index Diet (LGID) A.2 Route of Admi

Sponsors

ICMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Inclusion Criteria of cases o Age 18 to 35 years old, with confirmed clinical diagnosis for PCOS with Rotterdam criteria. b) Inclusion Criteria of controls o Healthy females of 18-35 year age with BMI matched with regular menstrual cycles exhibiting no recent changes in menstrual patterns or abnormal elevations in follicle-stimulating hormone [FSH]).

Exclusion criteria

Exclusion criteria: c) Exclusion Criteria o Pregnant and/or lactating mothers o Use of hormonal birth control methods or fertility medications during the prior 3 months. o Women taking anti-seizure or anti-psychotic medications known to induce menstrual irregularity, hypolipidemic agents, antihypertensive medications, or antiaggregant/anticoagulants.. o Any medical history of conditions known to interfere with reproductive or metabolic function (besides PCOS) or bone and muscle metabolism, including diabetes mellitus, hyperprolactinemia, untreated thyroid dysfunction, premature ovarian failure, cushing disease, congenital adrenal hyperplasia, hyperparathyroidism, rheumatoid arthritis, renal disease, chronic obstructive pulmonary disease, and osteoporosis.

Design outcomes

Primary

MeasureTime frame
Prevalence of SOTimepoint: At baseline

Secondary

MeasureTime frame
The efficacy of individualised lifestyle modifications among sarcopenic obese individuals will be done after repeating the DEXA and the Inflammatory marker hsCRP, insulin resistivity HOMA-IR, lipid profile, levels of HbA1C, vitamin-D levels at 12-weeks post intervention.Timepoint: 12 weeks

Countries

India

Contacts

Public ContactDr Deepali Garg

AIIMS Delhi

drdeepaligrag@gmail.com9818706660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026